Switch theme
Sign up to access all valuation multiples
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
2017
368
LTM Revenue $236M
LTM EBITDA -$251M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SpringWorks Therapeutics has a last 12-month revenue of $236M and a last 12-month EBITDA of -$251M.
In the most recent fiscal year, SpringWorks Therapeutics achieved revenue of $192M and an EBITDA of -$275M.
SpringWorks Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SpringWorks Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.4M | $192M | XXX | XXX | XXX |
| Gross Profit | n/a | $5.0M | XXX | XXX | XXX |
| Gross Margin | NaN% | 3% | XXX | XXX | XXX |
| EBITDA | -$341M | -$275M | XXX | XXX | XXX |
| EBITDA Margin | -6267% | -143% | XXX | XXX | XXX |
| Net Profit | -$277M | -$325M | XXX | XXX | XXX |
| Net Margin | -5093% | -170% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SpringWorks Therapeutics's stock price is $37.
SpringWorks Therapeutics has current market cap of $2.8B, and EV of $2.5B.
See SpringWorks Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.8B | XXX | XXX | XXX | XXX | $-3.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SpringWorks Therapeutics has market cap of $2.8B and EV of $2.5B.
SpringWorks Therapeutics's trades at 10.6x LTM EV/Revenue multiple, and -10.0x LTM EBITDA.
Analysts estimate SpringWorks Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SpringWorks Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 13.1x | XXX | XXX | XXX |
| EV/EBITDA | -9.1x | XXX | XXX | XXX |
| P/E | -10.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSpringWorks Therapeutics's NTM/LTM revenue growth is 80%
SpringWorks Therapeutics's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, SpringWorks Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SpringWorks Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SpringWorks Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3417% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -143% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -63% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 134% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 105% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 239% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SpringWorks Therapeutics acquired XXX companies to date.
Last acquisition by SpringWorks Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . SpringWorks Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SpringWorks Therapeutics founded? | SpringWorks Therapeutics was founded in 2017. |
| Where is SpringWorks Therapeutics headquartered? | SpringWorks Therapeutics is headquartered in United States of America. |
| How many employees does SpringWorks Therapeutics have? | As of today, SpringWorks Therapeutics has 368 employees. |
| Who is the CEO of SpringWorks Therapeutics? | SpringWorks Therapeutics's CEO is Mr. Saqib Islam, J.D.. |
| Is SpringWorks Therapeutics publicy listed? | Yes, SpringWorks Therapeutics is a public company listed on NAS. |
| What is the stock symbol of SpringWorks Therapeutics? | SpringWorks Therapeutics trades under SWTX ticker. |
| When did SpringWorks Therapeutics go public? | SpringWorks Therapeutics went public in 2019. |
| Who are competitors of SpringWorks Therapeutics? | Similar companies to SpringWorks Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SpringWorks Therapeutics? | SpringWorks Therapeutics's current market cap is $2.8B |
| What is the current revenue of SpringWorks Therapeutics? | SpringWorks Therapeutics's last 12-month revenue is $236M. |
| What is the current EBITDA of SpringWorks Therapeutics? | SpringWorks Therapeutics's last 12-month EBITDA is -$251M. |
| What is the current EV/Revenue multiple of SpringWorks Therapeutics? | Current revenue multiple of SpringWorks Therapeutics is 10.6x. |
| What is the current EV/EBITDA multiple of SpringWorks Therapeutics? | Current EBITDA multiple of SpringWorks Therapeutics is -10.0x. |
| What is the current revenue growth of SpringWorks Therapeutics? | SpringWorks Therapeutics revenue growth between 2023 and 2024 was 3417%. |
| Is SpringWorks Therapeutics profitable? | Yes, SpringWorks Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
